Haleon plc (HLN) Stock Price & How to Invest

Haleon plc is one of the world's largest standalone consumer-health companies, created when GSK demerged its consumer division in 2022. It sells everyday over-the-counter products across five categories: Oral Health (Sensodyne, parodontax, Polident), Pain Relief (Advil, Panadol, Voltaren, Excedrin), Respiratory Health (Theraflu, Otrivin), Vitamins, Minerals and Supplements (Centrum, Emergen-C), and Digestive Health and Therapeutic Skin Health (Tums, Fenistil). The company generated roughly 11 billion pounds (about ~$14 billion) of revenue in 2025 and about 11.15 billion pounds over the twelve months to June 2026, and holds leading or top-tier positions in many of its categories, which gives it pricing power and broad global distribution across pharmacy, grocery, and e-commerce channels.

The investment picture centers on Haleon as a defensive compounder. Growth is driven by trusted brands, innovation launches, and expansion in emerging markets, while management has focused on margin expansion, debt reduction, and returning cash through dividends and buybacks. Pfizer, a legacy shareholder from the GSK-Pfizer consumer joint venture, fully exited its stake in 2025, removing a long-standing overhang. Revenue was about 2.86 billion pounds in Q1 2026 and about 2.75 billion pounds in Q2, with latest-quarter growth of about 2.2%. Sentiment cooled in late September 2026 when J.P. Morgan rated the shares underweight, tracked Q3 organic growth at about 3% (the bottom of guidance) on a weaker European outlook, and said it expects the medium-term growth target to be reset in February 2027. The trade-off is that a slow-and-steady category (single-digit organic growth) means the stock is valued as a stable consumer-staples name rather than a high-growth story, so returns depend heavily on execution, currency, and valuation.

Organic growth has run at the low end of category norms (about 3% in 2025), pressured by a weak cold and flu season and soft North American consumer confidence, and J.P. Morgan's tracking puts 2026 at the bottom of the 3-5% guidance range again, so a slow-growth profile is a persistent concern; a reset of the 4-6% medium-term target in February 2027 is a live possibility. The Q4 outlook depends on the cold and flu season. The US pain market has been weak, weighing on Advil despite share gains. Haleon competes against far larger, deeper-pocketed rivals, faces private-label pressure, and carries meaningful debt from its demerger (about 8.3 billion pounds against roughly 0.8 billion of cash). As a UK-based company reporting in pounds, ADR holders are exposed to currency swings, and regulatory or product-liability issues in over-the-counter categories are an ongoing tail risk.

5 analysts publish price targets on HLN, averaging $11.93 against a $10.13 price as of October 2026, or +17.8%. The published targets run from $10.00 to $13.77, a moderate spread, and the ratings split 3 buy, 2 hold, 0 sell. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full HLN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Haleon plc. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Oral Health leadership. Oral Health is Haleon's standout engine, growing around 8% organically in 2025 and posting double-digit growth in early 2026, led by Sensodyne and parodontax. The most optimistic published target, $13.77, assumes this works close to its best case.

The case against. Organic growth has run at the low end of category norms (about 3% in 2025), pressured by a weak cold and flu season and soft North American consumer confidence, and J.P. The most pessimistic target, $10.00, is roughly what HLN is worth if this bites instead.

Read the full bull and bear case on HLN, including what would have to change to break either one. Walnut is not an investment adviser.

No. Haleon plc (HLN) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Haleon plc's investor relations page or your broker.

• Revenue (TTM): ~£11.15B (FY2025 ~£11.0B, ~$14B)
• Q2 2026 revenue: ~£2.75B (latest-quarter growth ~2.2%)
• Margins (TTM): ~66% gross, ~24% operating, ~15% net
• Net income (TTM): ~£1.6B
• Market cap: ~$44B (ADR ~$10.06 on October 16, 2026)
• P/E (trailing / forward): ~20x / ~16x
• Dividend yield: ~2% (payout ~40% of earnings)

Haleon trades at about 20 times trailing and 16 times forward earnings, broadly in line with large consumer-staples peers, which prices in its defensive, cash-generative profile rather than a growth premium. Management guides to 3-5% organic revenue growth for 2026, but analyst tracking points to the bottom of that range, and the five covering analysts in the US data carry a mean ADR target near $11.93. The Q3 trading update on October 29, 2026 is the next read; figures are approximate and vary with currency and reporting conventions for the ADR.

Other names that sit close to HLN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get HLN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so HLN sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where HLN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Haleon is a large, cash-generative consumer-health owner of everyday brands whose appeal rests on steady organic growth and margin expansion rather than rapid top-line acceleration. The open question going into its October 29, 2026 trading update is whether growth stays at the bottom of the 3-5% range for a second year.

Whether HLN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is HLN a buy or a sell?, and where the stock could go from here in the HLN stock forecast.

For income investors, whether HLN pays a dividend and how the payout looks is covered in does HLN pay a dividend? And to weigh HLN against a peer, read the full side-by-side comparisons: HLN vs KVUE and HLN vs CL.